Page 2 - Randomized Phase News Today

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Trial is Supported by Stand Up To Cancer as Part of an Initiative to Find Treatments for the ~70% of Gastroesophageal Cancer (GEC) Patients for Whom Current…

Initial interim landmark data analysis will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024...

SHANGHAI, China, Jan. 17, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*).32 out of 42 patients treated since 2022

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 46th annual San Antonio Breast Cancer Symposium, December 5–9, 2023.

Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial Indicate That Prior Use of Trilaciclib with Cytotoxic…

- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved...

Initial interim landmark data analysis to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at 4:20 p.m. ET ...

Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.